In 1978, following a specific request from the Thalassaemia Centre of the University of Turin, the company designed a portable infuser for the treatment of thalassaemia.
All this has led to the creation of a series of drug-delivery pumps dedicated to the treatment of various pathologies. Canè microinfusers respond effectively to the required therapeutic needs as they are designed in close collaboration with clinicians and patients.
CANÈ SpA aims to protect its name, its history, and its identity.
Offering quality services to customers, representing a valid reference and support for the latter.
Always satisfying your customers through the services, products and prices offered within a context of maximum respect.
The safety and precision standards are very high thanks to the numerous checks carried out on each component and the know-how acquired by the company over time.
To carry out its work, CANÈ participates in numerous conferences, in Italy and abroad, taking an interest in new therapies in collaboration with pharmaceutical companies, doctors and patients. Canè SpA, in collaboration with numerous pharmaceutical companies, has also been collaborating for some time on international multicentre studies in the search for new therapeutic solutions for various rare diseases. Adapting to the demands of international customers has seen the company achieve a leadership position in its areas of competence.
CANÈ SpA aims to contribute to improving people's quality of life by designing, manufacturing and marketing infusion systems and accessories for the treatment and care of multiple diseases, respecting the health and safety of its employees and collaborators, of its customers, of people who live near the production unit, and in general of all those with whom they maintain professional or other relationships.
Blood transfusions are a life-saving treatment for many patients with chronic anaemia including beta-thalassaemia, myelodysplasia and sickle cell anaemia. Each unit of transfused blood contains 200-250 mg of iron; the human body has no active elimination mechanisms for excess iron, and so iron overload is an inevitable consequence of chronic transfusion therapy.
Parkinson's disease is a central nervous system disorder caused by the degeneration of a number of neurons, predisposed to produce a neurotransmitter called dopamine, located in the part of the brain called the substantia nigra.
Currently, “palliative care” is defined as “active holistic care, offered to people of all ages who suffer from intense health-related suffering resulting from serious illness, especially those who are at the end of their lives".
Pulmonary arterial hypertension (PAH) is a rare, progressive respiratory disease characterised by dangerously high blood pressure and vascular resistance; this causes progressive fatigue in the right ventricle that can culminate in even fatal heart failure